Citadel Advisors
NUVB icon

Citadel Advisors’s Nuvation Bio NUVB Stock Holding History

Citadel Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Sell
1,988,330
-77,081
-4% -$377K ﹤0.01% 3389
2026
Q1 		$8.86M Buy
2,065,411
+1,930,412
+1,430% +$10.8M ﹤0.01% 3425
2025
Q4 		$1.21M Sell
134,999
-2,169,454
-94% -$13.4M ﹤0.01% 6982
2025
Q3 		$8.53M Sell
2,304,453
-3,228,523
-58% -$8.8M ﹤0.01% 3500
2025
Q2 		$10.8M Buy
5,532,976
+3,427,130
+163% +$7.14M ﹤0.01% 2924
2025
Q1 		$3.71M Sell
2,105,846
-72,116
-3% -$164K ﹤0.01% 4389
2024
Q4 		$5.79M Sell
2,177,962
-580,397
-21% -$1.49M ﹤0.01% 3727
2024
Q3 		$6.32M Buy
2,758,359
+762,142
+38% +$2.32M ﹤0.01% 3570
2024
Q2 		$5.83M Sell
1,996,217
-103,378
-5% -$315K ﹤0.01% 3516
2024
Q1 		$7.64M Sell
2,099,595
-877,707
-29% -$1.69M ﹤0.01% 3319
2023
Q4 		$4.5M Buy
2,977,302
+527,446
+22% +$679K ﹤0.01% 3950
2023
Q3 		$3.28M Buy
2,449,856
+38,175
+2% +$63.5K ﹤0.01% 4327
2023
Q2 		$4.34M Sell
2,411,681
-448,189
-16% -$762K ﹤0.01% 3859
2023
Q1 		$4.75M Sell
2,859,870
-2,455,161
-46% -$4.98M ﹤0.01% 3913
2022
Q4 		$10.2M Sell
5,315,031
-328,714
-6% -$665K ﹤0.01% 2810
2022
Q3 		$12.6M Buy
5,643,745
+21,510
+0.4% +$61.4K ﹤0.01% 2425
2022
Q2 		$18.2M Sell
5,622,235
-362,988
-6% -$1.58M ﹤0.01% 1935
2022
Q1 		$31.5M Buy
5,985,223
+480,952
+9% +$2.7M 0.01% 1500
2021
Q4 		$46.8M Sell
5,504,271
-141,018
-2% -$1.3M 0.01% 1218
2021
Q3 		$56.1M Sell
5,645,289
-756,400
-12% -$6.86M 0.01% 1038
2021
Q2 		$57.9M Sell
6,401,689
-184,985
-3% -$2.11M 0.01% 1014
2021
Q1 		$68.8M Buy
6,586,674
+4,086,050
+163% +$45.7M 0.02% 796
2020
Q4 		$29.3M Buy
+2,500,624
New +$26M 0.01% 1415

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Citadel Advisors's NUVB Position: Q2 2026 in Review

Citadel Advisors reduced its Nuvation Bio (NUVB) stake by 3.7% in Q2 2026, selling an estimated $377K and leaving 1,988,330 shares worth $11.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3389.

Citadel Advisors first reported a position in NUVB in Q4 2020 and has held it in 23 quarters since. The position peaked at $68.8M in Q1 2021. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Citadel Advisors held 1,988,330 shares of Nuvation Bio worth $11.3M as of Q2 2026.
  • Citadel Advisors sold 77,081 Nuvation Bio shares in Q2 2026, an estimated $377K.
  • Nuvation Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3389 holding.
  • Citadel Advisors first reported a position in Nuvation Bio in Q4 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Nuvation Bio position peaked at $68.8M in Q1 2021.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.